RAPT Therapeutics

RAPT Therapeutics is a clinical-stage biopharmaceutical company developing oral small-molecule and antibody therapies for patients with inflammatory, immunologic, and oncologic diseases. Its pipeline centers on ozureprubart, a long-acting anti-IgE antibody candidate in Phase 2 trials for food allergies, alongside programs targeting key drivers of immune response. The company was acquired by GSK in January 2026. It was surfaced as a portfolio company of GV and added to the API Evangelist network; as a life-sciences therapeutics company it publishes no public API, developer portal, or machine-readable API surface.

RAPT Therapeutics is profiled on the APIs.io network. Tagged areas include Company, Life Sciences, Biotechnology, Pharmaceuticals, and Immunology.

3.3/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-08-20 · rubric v0.12.0
0 APIs
CompanyLife SciencesBiotechnologyPharmaceuticalsImmunologyOncologyClinical Trials

Kin Score

Kin Score Kin Score How this is scored →
scored 2026-08-20 · rubric v0.12.0
Composite quality — 3.3/100 · minimal
Contract Quality 0.0 / 21
Developer Ergonomics 0.0 / 17
Access Clarity 0.0 / 17
Operational Transparency 0.0 / 11
Contract Governance 0.0 / 10
Discoverability 4.3 / 9
Regulatory Posture 1.1 / 15
Agent readiness — 0/100 · human only
Machine-Readable Contract 0 / 18
Agentic Access Contract 0 / 10
Documented Reversibility 0 / 6
MCP Server 0 / 12
Machine-Readable Auth 0 / 10
Idempotency 0 / 9
Stable Error Semantics 0 / 8
Request/Response Examples 0 / 7
Rate-Limit Signaling 0 / 7
Typed Event Surface 0 / 6
Agent Skills 0 / 5
Well-Known Catalog 0 / 4
Consent & Bot Identity 0 / 3
A2A Agent Card 0 / 8
Dry-Run / Simulate Mode 0 / 4
Regulatory Posture applies to this provider. Its tags matched the Health regime, so Regulatory Posture carries 15 points of the composite. If this regime is wrong for your business, say so on your provider repo — the applicability map is public and we will correct it.
The six quality facets above are damped to 85 points between them, because the conditional facet above carries the other 15. That is why each facet's contribution is shown against a damped maximum: raising a quality facet moves the composite by 85% of its nominal weight, not 100%. The full arithmetic is at apis.io/rating/.
Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/rapt-therapeutics: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Security Posture 1

Authentication, domain security, vulnerability disclosure, and trust-center signals.

Rapt Therapeutics Domain Security

TLSv1.3 · HSTS · DMARC

SECURITY

Resources

Access & Security 1

Authentication, authorization, and security posture

Company 1

The organization behind the API

Source (apis.yml)

apis.yml Raw ↑
aid: rapt-therapeutics
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/icons/rapt-therapeutics.png
name: RAPT Therapeutics
description: RAPT Therapeutics is a clinical-stage biopharmaceutical company developing oral small-molecule and antibody therapies
  for patients with inflammatory, immunologic, and oncologic diseases. Its pipeline centers on ozureprubart, a long-acting
  anti-IgE antibody candidate in Phase 2 trials for food allergies, alongside programs targeting key drivers of immune response.
  The company was acquired by GSK in January 2026. It was surfaced as a portfolio company of GV and added to the API Evangelist
  network; as a life-sciences therapeutics company it publishes no public API, developer portal, or machine-readable API surface.
url: https://raw.githubusercontent.com/api-evangelist/rapt-therapeutics/refs/heads/main/apis.yml
x-type: company
x-source: vc-portfolio
x-backed-by:
- gv
x-tier: stub
x-tier-reason: portfolio-lead
specificationVersion: '0.23'
created: '2026-07-17'
modified: '2026-07-20'
tags:
- Company
- Life Sciences
- Biotechnology
- Pharmaceuticals
- Immunology
- Oncology
- Clinical Trials
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: DomainSecurity
  url: security/rapt-therapeutics-domain-security.yml
- type: Website
  url: https://rapt.com
x-enrichment:
  date: '2026-07-20'
  status: minimal
  artifacts_added: 1
  pass: local-v1